AI English summary of an SEC filing — figures as filed
Abbott Laboratories ABTThe company said net sales for Q2 2025 rose to $11,142 million, up from $10,377 million a year earlier, an increase of 7.4% on a reported basis and 6.9% on an organic basis. Excluding COVID-19 testing-related sales, organic growth was 7.5%.
Key points
AI summaryThe company said net sales for Q2 2025 rose to $11,142 million, up from $10,377 million a year earlier, an increase of 7.4% on a reported basis and 6.9% on an organic basis. Excluding COVID-19 testing-related sales, organic growth was 7.5%.
The company said its GAAP net earnings for Q2 were $1,779 million, and its GAAP diluted EPS was $1.01. Adjusted diluted EPS, which excludes specified items, was $1.26, and adjusted net earnings were $2,213 million.
Abbott said Medical Devices sales for Q2 were $5,369 million, up 13.4% on a reported basis and 12.2% on an organic basis. It said sales of continuous glucose monitors in Diabetes Care were $1.9 billion, up 21.4% on a reported basis.
The company projected full-year 2025 adjusted diluted EPS of $5.10 to $5.20. It also projected organic sales growth of 7.5% to 8.0% excluding COVID-19 testing-related sales, or 6.0% to 7.0% including them.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Abbott Q2 sales of $11,142 million, up 7.4% reported
The company said net sales for Q2 2025 rose to $11,142 million, up from $10,377 million a year earlier, an increase of 7.4% on a reported basis and 6.9% on an organic basis. Excluding COVID-19 testing-related sales, organic growth was 7.5%.
Source · Based on the filing body and exhibits
Abbott Q2 GAAP diluted EPS $1.01, adjusted EPS $1.26
The company said its GAAP net earnings for Q2 were $1,779 million, and its GAAP diluted EPS was $1.01. Adjusted diluted EPS, which excludes specified items, was $1.26, and adjusted net earnings were $2,213 million.
Source · Based on the filing body and exhibits
Abbott Medical Devices Q2 sales $5,369 million, Diabetes Care included
Abbott said Medical Devices sales for Q2 were $5,369 million, up 13.4% on a reported basis and 12.2% on an organic basis. It said sales of continuous glucose monitors in Diabetes Care were $1.9 billion, up 21.4% on a reported basis.
Source · Based on the filing body and exhibits
Abbott 2025 outlook: organic sales growth and adjusted diluted EPS
The company projected full-year 2025 adjusted diluted EPS of $5.10 to $5.20. It also projected organic sales growth of 7.5% to 8.0% excluding COVID-19 testing-related sales, or 6.0% to 7.0% including them.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…